The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Lokavant provides clinical trial intelligence
Advances Amgen's mission to serve patients with rare disease medicines
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
